ASH 2023 | CAR-engineered NK cells for targeting CD25 in CML blast crisis
Ali Turhan, MD, PhD, University of Paris-Saclay, Paris, France, discusses the use of chimeric antigen-receptor (CAR)-engineered natural killer (NK) cells for targeting the CD25 antigen overexpressed in chronic myeloid leukemia (CML) blast crisis and in some patients with acute myeloid leukemia (AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Okay. So, actually, as you know, the NK-cells are important anticancer agents. And today we have the opportunity to target them to a known target but by CAR strategy. So what we are doing now, what we have done in this particular model, is to target CD25, which is an antigen overexpressed in blast crisis from CML patients – chronic myeloid leukemia. And interestingly, what we have been able to show is that the use of these particular CAR-NK cells targeting CD25 is able to prolong the survival of mice, you know, which is in this mice model with leukemia...
Okay. So, actually, as you know, the NK-cells are important anticancer agents. And today we have the opportunity to target them to a known target but by CAR strategy. So what we are doing now, what we have done in this particular model, is to target CD25, which is an antigen overexpressed in blast crisis from CML patients – chronic myeloid leukemia. And interestingly, what we have been able to show is that the use of these particular CAR-NK cells targeting CD25 is able to prolong the survival of mice, you know, which is in this mice model with leukemia. And what we are doing now is to translate this to induced pluripotent stem cell technology, in which we will be able to generate NK-cells harboring this CAR and generating NK-cells from this, CAR-NK cells, which will be universal because they are from these induced pluripotent stem cells. And then we hope to go to the clinic with this essentially in patients with blast crisis in CML, but also in AML patients because we know that in acute myeloid leukemia, you have also some overexpression of genes, the CD25 antigen in some patients.
Read more...
